Aion Therapeutic Statistics
Total Valuation
Aion Therapeutic has a market cap or net worth of 3.36 million. The enterprise value is 5.04 million.
| Market Cap | 3.36M |
| Enterprise Value | 5.04M |
Important Dates
The next estimated earnings date is Monday, December 30, 2024.
| Earnings Date | Dec 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +131.73% |
| Shares Change (QoQ) | +11.19% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 437.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.10 |
| EV / Sales | 9.05 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.20
| Current Ratio | 0.20 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.62 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -116.83% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 116,169 |
| Profits Per Employee | -916,425 |
| Employee Count | 5 |
| Asset Turnover | 1.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.70% in the last 52 weeks. The beta is 0.55, so Aion Therapeutic's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +2.70% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 45.39 |
| Average Volume (20 Days) | 81,907 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aion Therapeutic had revenue of 580,845 and -4.58 million in losses. Loss per share was -0.01.
| Revenue | 580,845 |
| Gross Profit | 258,108 |
| Operating Income | -925,840 |
| Pretax Income | -4.58M |
| Net Income | -4.58M |
| EBITDA | n/a |
| EBIT | -925,840 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 58,607 in cash and 1.81 million in debt, giving a net cash position of -1.75 million.
| Cash & Cash Equivalents | 58,607 |
| Total Debt | 1.81M |
| Net Cash | -1.75M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -2.93M |
| Book Value Per Share | -0.01 |
| Working Capital | -3.04M |
Cash Flow
| Operating Cash Flow | -835,707 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 44.44% |
| Operating Margin | -159.40% |
| Pretax Margin | -788.87% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | -159.40% |
| FCF Margin | n/a |
Dividends & Yields
Aion Therapeutic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -131.73% |
| Shareholder Yield | -131.73% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Aion Therapeutic has an Altman Z-Score of -37.05. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -37.05 |
| Piotroski F-Score | n/a |